Teplizumab Treatment Preserves Beta Cells in New Cases of Type 1 Diabetes
Phase 2 trials have shown that the anti-CD3 monoclonal antibody drug Teplizumab significantly reduces the loss of insulin-producing pancreatic beta cells for subjects newly diagnosed…